SCIEX, a global leader in life science analytical technologies, has announced their alliance with Children’s Medical Research Institute (CMRI) to equip The Australian Cancer Research Foundation International Centre for the Proteome of Cancer (ProCan™) facility with the solutions and tools required for the advancement of their large-scale proteomic profiling studies. These studies will profile thousands of tumour samples per year, enable discoveries around the causes of cancer, provide guidance of cancer treatment options, and work to produce standard operating procedures for other facilities around the world. ProCan will be established with $10 million in seed money from The Australian Cancer Research Foundation to purchase the SCIEX equipment.
The agreement provides ProCan with the high sample throughput required for the industrialisation of proteomics via a large suite ofSCIEX TripleTOF® 6600 mass spectrometers and NanoLC 400 HPLCs, to create one of the world's largest scale implementations of the SCIEX next-generation proteomics solution, featuring SWATH® Acquisition and OneOmics cloud computing. Additionally ProCan will benefit from SCIEX’s exclusive collaborators, Pressure Biosciences and Beckman Coulter, using Pressure Cycling Technology and liquid handling workstations for increased protein quantitation and reproducibility.
"Large-scale proteomics studies have great potential to improve our understanding of cancer at the molecular level, but are subject to significant variability caused in sample preparation, data acquisition and interpretation," said Chris Radloff, Global Vice President and General Manager of the LC-MS Business at SCIEX. "Through our partnership with CMRI and the designation of ProCan as a SCIEX Centre of Innovation in Precision Medicine, SCIEX solutions reduce that variability and enable higher sample throughput, which will help to accelerate cancer research and precision medicine at large."
"Collaborating with SCIEX will enable ProCan to accomplish our vision of one day, delivering a proteomics report on every clinician's desk," said Professor Phil Robinson, Head of the Cell Signalling Unit at CMRI and co-developer of ProCan with Professor Roger Reddel, Head of CMRI's Cancer Research Unit. "The unique industrial proteomics platform we are developing will unlock the potential of our discoveries and empower us to perform the translation research needed to rapidly identify the cause of each individual cancer, advancing scientific discovery and allowing a more accurate prediction of the best cancer treatments for individual patients."
SCIEX will designate ProCan as a "SCIEX Centre of Innovation in Precision Medicine" and will include SCIEX scientists working with researchers from CMRI to develop and trial new omics workflows in a real-world setting. SCIEX and CMRI will discuss further details about the centre at the 21st Annual Lorne Proteomics Symposium 2016."
Scientists from SCIEX will be presenting Multi-Omics workshops and poster presentations at the 21st Annual Lorne Proteomics Symposium 2016, held February 4th through the 7th at Mantra Lorne, Lorne Victoria.